---
title: "Bronstein, Gewirtz & Grossman, LLC Encourages GSK plc (GSK) Stockholders to Inquire about Securities Investigation"
description: "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for GSK plc stockholders following a negative FDA advisory vote on GSK's Blenrep treatment. This announcement led to a 4.73% drop i"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251033168.md"
published_at: "2025-07-31T15:00:01.000Z"
---

# Bronstein, Gewirtz & Grossman, LLC Encourages GSK plc (GSK) Stockholders to Inquire about Securities Investigation

> Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for GSK plc stockholders following a negative FDA advisory vote on GSK's Blenrep treatment. This announcement led to a 4.73% drop in GSK's ADR price on July 17, 2025. Investors who purchased GSK securities are encouraged to participate in the investigation by visiting the firm's website. The firm operates on a contingency fee basis, meaning no upfront costs for investors.

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc ("GSK" or "the Company") . Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GSK.

**Investigation Details**

On July 17, 2025, GSK issued a press release announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations." On this news, GSK's American Depositary Receipt ("ADR") price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025.

**What's Next?**

If you are aware of any facts relating to this investigation or purchased GSK securities, you can assist this investigation by visiting the firm's site: bgandg.com/GSK. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

**There is No Cost to You**

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

**Why Bronstein, Gewirtz & Grossman**

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

**Contact**

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

**SOURCE:** Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

### Related Stocks

- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK - GlaxoSmithKline plc](https://longbridge.com/en/quote/GSK.UK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 葛兰素史克获得欧洲委员会对 Exdensur 的批准 | 葛兰素史克：葛兰素史克 - 欧洲委员会批准的 EXDENSUR | [Link](https://longbridge.com/en/news/276102835.md) |
| 葛兰素史克启动最多达 4.5 亿英镑的股票回购批次 | 葛兰素史克启动高达 4.5 亿英镑的股票回购计划 | [Link](https://longbridge.com/en/news/276103252.md) |
| 贝伦贝格银行维持对葛兰素史克（GSK）的持有评级 | Berenberg Bank 分析师 Kerry Holford 对葛兰素史克 (GSK) 维持了持有评级，目标价为 20.00 英镑。Holford 专注于医疗保健行业，推荐股票的平均回报率为 9.7%，成功率为 59.14%。此外，美国 | [Link](https://longbridge.com/en/news/276103203.md) |
| 葛兰素史克启动 4.5 亿英镑的股票回购计划，因欧盟批准 Exdensur 药物 | 葛兰素史克（GSK PLC）已启动其 20 亿英镑回购计划的第四个批次，价值为 4.5 亿英镑，预计将在 4 月 24 日之前完成。同时，欧洲委员会批准了 Exdensur，这是一种抗哮喘药物，标志着其获得的第四个监管批准。此次回购将由巴黎 | [Link](https://longbridge.com/en/news/276127242.md) |
| 葛兰素史克启动了第四批股票回购，金额最高可达 4.5 亿英镑，这是其 20 亿英镑回购计划的一部分 | 英国制药巨头葛兰素史克（GSK plc）宣布启动其 20 亿英镑股票回购计划的第四个阶段，计划回购高达 4.5 亿英镑的股份。这是在完成前三个阶段之后的举措。此次回购是 GSK 将多余资本返还给股东并提升每股收益的战略的一部分。股票购买将于 | [Link](https://longbridge.com/en/news/276103384.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
